Join us on Tuesday, March 16^th for this NCPD-accredited webinar
5:00 PM – 6:00 PM ET

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Tuesday, March 16, 2021
5:00 PM – 6:00 PM Eastern Time
Live NCPD-accredited webinar

Topics to Be Discussed

• Identification of the clinical and prognostic significance of cytogenetic and molecular defects in acute myeloid leukemia (AML)
• Evaluation of the effects of biologic and disease-related factors on the selection and sequencing of available therapies for patients with AML
• Recognition of the side effects and toxicities associated with existing and recently approved therapies in the management of AML

Target Audience
This activity has been designed to meet the educational needs of registered nurses, nurse practitioners and clinical nurse specialists involved in the treatment of acute myeloid leukemia (AML).

Learning Objectives
Upon completion of this activity, participants should be able to

• Recognize the clinical and prognostic significance of specific cytogenetic and molecular abnormalities, and use this information to develop, adapt or refine diagnostic testing and management algorithms for patients with AML.
• Evaluate the importance of patient age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for various presentations of AML.
• Recognize the FDA approval of venetoclax for patients with newly diagnosed AML not eligible for intensive therapy, and discern how this agent can be optimally integrated into nonresearch care algorithms for these patients.
• Assess published research evidence with commercially available FLT3 inhibitors, and use this information to present clinical care opportunities to appropriate patients with newly diagnosed or progressive AML with FLT3 mutations.
• Develop an understanding of the mechanism of action of, published data with and current therapeutic role of available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and IDH1 or 2 mutations.
• Review Phase III data documenting the efficacy of CC-486 as maintenance therapy for patients with newly diagnosed AML who achieved first complete response or complete response with incomplete blood count recovery with induction chemotherapy, and identify individuals appropriate for treatment with this newly FDA-approved agent.
• Design and implement a plan of care to prevent, recognize and manage side effects and toxicities associated with recently approved systemic therapies for AML to support quality of life and continuation of therapy.

Accreditation Statements
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Webinars/NCPD2021/AML/Mar16/ILNA

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

FACULTY — Ms Hewitt has no relevant conflicts of interest to disclose. The following faculty (and his spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Levis – Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc, Menarini Group, Takeda Oncology; Contracted Research: Astellas, FUJIFILM Pharmaceuticals USA Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporter
This activity is supported by an educational grant from Genentech, a member of the Roche Group.